Risk Stratification and Early Alerting Regarding COVID-19 Hospitalization (RiskSEARCH)

Current Health

Status: Terminated

Conditions: Covid19

Treatments: Device: Current Health

Study type: Observational

Funder types: Industry; Other U.S. Federal agency

Identifiers

NCT04709068

Pro00047371

Details and patient eligibility

About

The purpose of this research is to remotely monitor individuals who have tested positive for COVID-19 to learn more about progression and recovery from the disease. Individuals who test positive for COVID-19 will wear the Current Health wearable device continuously and answer a brief series of questions on Current Health tablet daily for up to 30 days. The health data will be used to develop predictive models of hospitalization risk.

Enrollment: 8 patients

Sex: All

Ages: 21+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Living in the United States (contiguous states)
• Aged 21 years or older
• Able to provide documentation of +Polymerase Chain Reaction (PCR) or +antigen test for COVID-19 within the past 48 hours
• Self-reports that comfortable and willing to wear the wearable device and interact with a tablet-based interface daily
• Able to provide a next of kin/designated person who can be contacted in the event of hospitalization for follow up.

Exclusion criteria

• Under the age of 21
• Received a positive test result more than 48 hours prior to contacting study staff or has a pending test for COVID-19
• Cannot confirm a PCR or antigen positive test for COVID-19
• Is unable to read English
• Is unwilling to wear the device 24 hours/day except for showering/bathing or interact with a tablet-based interface for daily questionnaire
• Is unwilling or unable to provide baseline data required for entry into the study
• Is unable to provide a next of kin/designated person who can be contacted in the event of hospitalization for follow-up
• Heavy tattooing on both upper arms
• Known atrial fibrillation (permanent or paroxysmal)
• Has taken/is taking part in a COVID-19 vaccine or treatment trial

Trial design

8 participants in 1 patient group

COVID19+

Treatment:

Device: Current Health